Engineered immune cells take on tough leukemia in early trial

NCT ID NCT07263906

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new type of immune cell therapy called LILRA6 CAR-T for people with acute myeloid leukemia that has come back or not responded to standard treatment. The therapy uses a patient's own T cells, modified in a lab to target leukemia cells. The study will enroll 48 participants to check safety and see if the treatment can shrink the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LILRA6 CAR-T cells (engineered immune cells)
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat acute myeloid leukemia.
What could go wrong: This is a very early Phase 1 trial with only 48 people, so it may not work or could have unexpected side effects. CAR-T therapy can cause severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT ACUTE MYELOID LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

The Second Affiliated Hospital,School of Medicine,Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.